The Bone Microenvironment and Therapeutic Resistance in Spinal Metastases: Mechanisms and Clinical Implications.

Spinal metastases represent a biologically distinct manifestation of systemic cancer, frequently progressing despite durable visceral response. The vertebral niche is defined by hypoxia, immune suppression, osteoclast-osteoblast coupling, and stromal signaling. These features create a therapeutic sanctuary that fosters tumor dormancy, clonal evolution, and resistance to systemic therapy. We aim to synthesize current knowledge of the bone niche in spinal metastases, explain how microenvironmental factors and tumor-intrinsic changes converge to drive therapeutic resistance, and provide translational implications for prognosis and treatment design. A narrative review of English-language studies (1990-2024) from PubMed and Scopus was conducted, examining pathophysiology, bone-tumor crosstalk, dormancy, immune evasion, and resistance genetics. Foundational pre-1990 works were included when biologically essential. When available, bone-specific outcomes (skeletal progression, skeletal-related events, spine-PFS) were prioritized. Spinal metastases are driven by unique interactions between tumor cells and the bone microenvironment, including RANK/RANKL signaling, hypoxia-induced HIF activation, immune sequestration, and dormancy niches. Specific molecular alterations include EGFR and ALK mutations in NSCLC, BRCA and PI3K/AKT pathway dysregulation in prostate and breast cancers, and VHL/HIF pathway alterations in RCC. Resistance patterns such as EGFR T790M and BRCA reversion mutations emerge disproportionately in bone, reflecting site-specific selective pressure. Conventional systemic therapies achieve lower efficacy in the spine, underscoring the need for site-specific biomarkers, advanced imaging, and tailored therapeutic strategies. The vertebral niche constitutes a treatment-resistant microenvironment where dormant tumor cells persist, immune surveillance is impaired, and resistant clones evolve. Integrating bone-microenvironment biology with molecular profiling, liquid biopsy, and advanced imaging is essential for refining prognostic models, guiding intervention timing, and designing spine-specific clinical trials. By reframing spinal metastases as a biologically and therapeutically distinct disease entity, this review establishes a framework for developing bone-directed treatment strategies and advancing precision oncology in metastatic spine care.